Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHR563
MIFTS: 48

Chronic Eosinophilic Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Chronic Eosinophilic Leukemia

About this section

MalaCards integrated aliases for Chronic Eosinophilic Leukemia:

Name: Chronic Eosinophilic Leukemia 12 58 36 15 70
Pdgfra-Associated Chronic Eosinophilic Leukemia 70

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Blood diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080367
KEGG 36 H01590
NCIt 50 C4563
ICD10 32 D47.5
ICD10 via Orphanet 33 D47.5
UMLS via Orphanet 71 C0346421
Orphanet 58 ORPHA168940
UMLS 70 C0346421 C3853548
Sources

Summaries for Chronic Eosinophilic Leukemia

About this section
KEGG : 36 Chronic eosinophilic leukemia (CEL) is a chronic myeloproliferative disease of unknown etiology in which a clonal proliferation of eosinophilic precursors results in a persistently elevated number of eosinophils in blood, bone marrow or peripheral tissues. In most patients with CEL (about 60%), eosinophils display PDGFRA-fusion genes and related cytogenetic defects. The most commonly detected oncoprotein is FIP1L1/PDGFRA. FIP1L1-PDGFRA is a constitutively activated tyrosine kinase, which is suggested to induce the proliferation of EoL-1 (The eosinophilic leukemia cell line) cells by inducing c-Myc expression at the mRNA level via ERK and JNK signaling pathways.

MalaCards based summary : Chronic Eosinophilic Leukemia, also known as pdgfra-associated chronic eosinophilic leukemia, is related to pdgfra-associated chronic eosinophilic leukemia and hypereosinophilic syndrome. An important gene associated with Chronic Eosinophilic Leukemia is FIP1L1 (Factor Interacting With PAPOLA And CPSF1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ketamine and Dextromethorphan have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and myeloid, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A chronic leukemia characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.

Wikipedia : 73 Chronic eosinophilic leukemia is a form of cancer in which too many eosinophils are found in the bone... more...

Sources

Related Diseases for Chronic Eosinophilic Leukemia

About this section

Diseases related to Chronic Eosinophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
# Related Disease Score Top Affiliating Genes
1 pdgfra-associated chronic eosinophilic leukemia 33.4 PDGFRA FIP1L1
2 hypereosinophilic syndrome 30.8 PDGFRB PDGFRA KIT JAK2 IL5 IFNA1
3 hypereosinophilic syndrome, idiopathic 30.7 WT1 PDGFRB PDGFRA KIT IL5 FIP1L1
4 myeloproliferative neoplasm 30.5 WT1 U2AF1 TET2 PDGFRB PDGFRA KIT
5 budd-chiari syndrome 30.3 PDGFRA JAK2 FIP1L1
6 endomyocardial fibrosis 30.3 PDGFRB PDGFRA IL5 FIP1L1 CHIC2
7 loeffler endocarditis 30.3 PDGFRA IL5 FIP1L1
8 myeloid sarcoma 30.2 U2AF1 KIT FLT3
9 acute leukemia 30.2 WT1 KIT JAK2 FLT3 FGFR1 ETV6
10 precursor t-cell acute lymphoblastic leukemia 30.1 FLT3 ETV6 ABL1
11 nail disorder, nonsyndromic congenital, 1 30.1 PDGFRB PDGFRA FIP1L1 FGFR1 ETV6
12 t-cell acute lymphoblastic leukemia 29.9 U2AF1 FLT3 ETV6 ABL1
13 thrombocytopenia 29.8 U2AF1 PDGFRA KIT JAK2 IFNA1 FLT3
14 deficiency anemia 29.7 U2AF1 KIT JAK2 IFNA1 FLT3 ABL1
15 mastocytosis 29.7 TET2 PDGFRB PDGFRA KIT JAK2 IFNA1
16 leukemia, acute lymphoblastic 29.6 WT1 U2AF1 KIT JAK2 FLT3 FGFR1
17 systemic mastocytosis 29.5 TET2 PDGFRB PDGFRA KIT JAK2 IFNA1
18 leukemia 29.4 WT1 U2AF1 TET2 KIT JAK2 FLT3
19 essential thrombocythemia 29.3 U2AF1 TET2 KIT JAK2 IFNA1 ASXL1
20 sm-ahnmd 29.2 U2AF1 TET2 PDGFRA KIT JAK2 FIP1L1
21 myeloid leukemia 29.2 WT1 U2AF1 TET2 KIT JAK2 FLT3
22 blood coagulation disease 29.2 U2AF1 TET2 KIT JAK2 IFNA1 FLT3
23 leukemia, chronic myeloid 29.2 WT1 U2AF1 PDGFRB PDGFRA KIT JAK2
24 juvenile myelomonocytic leukemia 29.2 U2AF1 TET2 PDGFRB PDGFRA JAK2 FLT3
25 myelofibrosis 29.2 WT1 U2AF1 TET2 PDGFRB KIT JAK2
26 myelodysplastic syndrome 29.0 WT1 U2AF1 TET2 PDGFRB KIT JAK2
27 atypical chronic myeloid leukemia 28.9 U2AF1 TET2 PDGFRB PDGFRA JAK2 FLT3
28 myelodysplastic/myeloproliferative neoplasm 28.9 U2AF1 TET2 PDGFRB PDGFRA KIT JAK2
29 polycythemia vera 28.7 U2AF1 TET2 PDGFRB PDGFRA KIT JAK2
30 leukemia, acute myeloid 28.4 WT1 U2AF1 TET2 PDGFRB PDGFRA KIT
31 pdgfrb-associated chronic eosinophilic leukemia 11.8
32 reticular perineurioma 10.4 PDGFRA KIT
33 deep leiomyoma 10.4 PDGFRA KIT
34 laryngeal small cell carcinoma 10.4 PDGFRA KIT
35 gastric leiomyoma 10.4 PDGFRA KIT
36 gastric leiomyosarcoma 10.4 PDGFRA KIT
37 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.4 KIT FLT3
38 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.4 JAK2 ABL1
39 pulmonary vein stenosis 10.4 PDGFRA KIT
40 acute myeloblastic leukemia with maturation 10.4 KIT FLT3
41 small intestine leiomyoma 10.4 PDGFRA KIT
42 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.4 PDGFRB PDGFRA FGFR1
43 mast-cell sarcoma 10.4 KIT FIP1L1
44 cytogenetically normal acute myeloid leukemia 10.4 WT1 FLT3
45 paraganglioma and gastric stromal sarcoma 10.3 PDGFRB PDGFRA KIT
46 desmoid tumor 10.3 PDGFRB PDGFRA KIT
47 sarcomatous intrahepatic cholangiocarcinoma 10.3 PDGFRB KIT
48 endometrial small cell carcinoma 10.3 PDGFRA KIT
49 splenomegaly 10.3
50 ovarian mixed germ cell neoplasm 10.3 WT1 KIT

Graphical network of the top 20 diseases related to Chronic Eosinophilic Leukemia:



Diseases related to Chronic Eosinophilic Leukemia
Sources

Symptoms & Phenotypes for Chronic Eosinophilic Leukemia

About this section

GenomeRNAi Phenotypes related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.43 FIP1L1 U2AF1
2 Decreased viability GR00173-A 10.43 FLT3 PDGFRA
3 Decreased viability GR00221-A-1 10.43 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
4 Decreased viability GR00221-A-2 10.43 ABL1 FGFR1 JAK2
5 Decreased viability GR00221-A-3 10.43 ABL1 PDGFRA PDGFRB
6 Decreased viability GR00221-A-4 10.43 FLT3 PDGFRA PDGFRB
7 Decreased viability GR00249-S 10.43 FIP1L1 IL5 OSM PDGFRA
8 Decreased viability GR00301-A 10.43 KIT
9 Decreased viability GR00342-S-1 10.43 ABL1 PDGFRB
10 Decreased viability GR00342-S-2 10.43 ABL1
11 Decreased viability GR00342-S-3 10.43 ABL1
12 Decreased viability GR00381-A-1 10.43 WT1
13 Decreased viability GR00386-A-1 10.43 CHIC2 FGFR1 FIP1L1 SIGLEC8
14 Decreased viability GR00402-S-2 10.43 PDGFRA U2AF1
15 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
16 Decreased substrate adherent cell growth GR00193-A-2 9.7 ABL1 KIT
17 Decreased substrate adherent cell growth GR00193-A-4 9.7 ABL1 FGFR1 FLT3 KIT
18 Resistant to vaccinia virus (VACV-A4L) infection GR00351-A-1 9.23 ABL1 FIP1L1 IFNA1 JAK2 OSM PDGFRA

MGI Mouse Phenotypes related to Chronic Eosinophilic Leukemia:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 ABL1 ASXL1 CDK5RAP2 ETV6 FGFR1 FLT3
2 hematopoietic system MP:0005397 10.31 ABL1 ASXL1 CDK5RAP2 CHIC2 ETV6 FGFR1
3 growth/size/body region MP:0005378 10.3 ABL1 ASXL1 CDK5RAP2 CHIC2 ETV6 FGFR1
4 immune system MP:0005387 10.28 ABL1 ASXL1 CDK5RAP2 CHIC2 ETV6 FGFR1
5 endocrine/exocrine gland MP:0005379 10.26 ABL1 ASXL1 CHIC2 ETV6 FGFR1 FLT3
6 embryo MP:0005380 10.15 ABL1 ETV6 FGFR1 IL5 JAK2 KIT
7 digestive/alimentary MP:0005381 10.11 ABL1 ASXL1 ETV6 FGFR1 IL5 KIT
8 mortality/aging MP:0010768 10.1 ABL1 ASXL1 CDK5RAP2 CHIC2 ETV6 FGFR1
9 craniofacial MP:0005382 10.07 ABL1 ASXL1 CDK5RAP2 FGFR1 KIT PDGFRA
10 integument MP:0010771 10.02 CDK5RAP2 CHIC2 ETV6 FGFR1 JAK2 KIT
11 liver/biliary system MP:0005370 9.92 ABL1 ASXL1 ETV6 IL5 JAK2 KIT
12 neoplasm MP:0002006 9.85 ASXL1 CDK5RAP2 ETV6 FLT3 IL5 JAK2
13 no phenotypic analysis MP:0003012 9.61 ETV6 FGFR1 FLT3 KIT PDGFRA SIGLEC8
14 normal MP:0002873 9.28 ABL1 ETV6 FGFR1 JAK2 KIT PDGFRA
Sources

Drugs & Therapeutics for Chronic Eosinophilic Leukemia

About this section

Drugs for Chronic Eosinophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
3
Acyclovir Approved Phase 3 59277-89-3 2022
4
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
7
Polyestradiol phosphate Approved Phase 3 28014-46-2
8
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
9
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
10
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
11
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
12 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
13 Neurotransmitter Agents Phase 3
14 Anesthetics, Dissociative Phase 3
15 Narcotics Phase 3
16 Excitatory Amino Acid Antagonists Phase 3
17 Analgesics, Opioid Phase 3
18 Analgesics Phase 3
19 Cola Phase 3
20 Antiparasitic Agents Phase 3
21 Antiprotozoal Agents Phase 3
22 Antiviral Agents Phase 3
23 valacyclovir Phase 3
24 Liver Extracts Phase 3
25 Amebicides Phase 3
26 Liposomal amphotericin B Phase 3
27 Anesthetics Phase 3
28 Anesthetics, Intravenous Phase 3
29 Anesthetics, General Phase 3
30 Estradiol 3-benzoate Phase 3
31 Contraceptive Agents Phase 3
32 Contraceptives, Oral Phase 3
33 Contraceptives, Oral, Combined Phase 3
34 Estradiol 17 beta-cypionate Phase 3
35 Norgestimate, ethinyl estradiol drug combination Phase 3
36
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
37
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
38
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
39
Caspofungin Approved Phase 2 179463-17-3, 162808-62-0 468682 2826718
40
alemtuzumab Approved, Investigational Phase 2 216503-57-0
41
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
42
Etoposide Approved Phase 2 33419-42-0 36462
43
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
44
Melphalan Approved Phase 2 148-82-3 4053 460612
45
Mesna Approved, Investigational Phase 2 3375-50-6 598
46
Carmustine Approved, Investigational Phase 2 154-93-8 2578
47
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
48
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
49
rituximab Approved Phase 2 174722-31-7 10201696
50
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
3 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
4 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
5 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
6 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
7 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
8 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
9 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
12 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
13 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
14 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
15 Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
16 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
17 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
18 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
19 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide
20 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
21 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
22 HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies Completed NCT00134017 Phase 2 Busulfan;Cyclophosphamide
23 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
24 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
25 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
26 Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
27 A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
28 Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
29 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
30 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
31 A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
32 A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration Via Intra-Bone Marrow Injection (Companion Protocol to MT2000-25) Terminated NCT00295880 Phase 1, Phase 2
33 Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
34 A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
35 Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation Terminated NCT00617929 Phase 2 clofarabine
36 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
37 Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI) Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
38 Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
39 T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
40 Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections Unknown status NCT00769613 Phase 1
41 Donor Mesenchymal Stem Cell Infusion for Treatment of Graft Versus Host Disease: A Phase I Trial Completed NCT00361049 Phase 1
42 Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-back of Non-alloreactive T Cells Completed NCT00104975 Phase 1 fludarabine phosphate;melphalan;tacrolimus;thiotepa
43 A Phase I Trial to Examine the Safety, Clinical, Immunologic and Virologic Effects of CMV pp65 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistent or Therapy Refractory Infections Completed NCT00509691 Phase 1
44 A Phase I Study of 5-AZA-2'-Deoxycytidine and Depsipeptide in Patients With Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease Completed NCT00114257 Phase 1 decitabine;romidepsin
45 Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies Completed NCT00104923 Phase 1 fenretinide
46 Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies Completed NCT00073944 Phase 1 forodesine hydrochloride
47 Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia Completed NCT00054236 Phase 1 cyclophosphamide;fludarabine phosphate;methylprednisolone
48 An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
49 A Dose Finding Study of R115777 (NSC 702818) in Patients With Advanced Hematologic Malignancies Completed NCT00005967 Phase 1 tipifarnib
50 Donor Natural Killer Cell Infusion for the Prevention of Relapse or Graft Failure After HLA-Haploidentical Familial Donor Bone Marrow Transplantation-A Phase I Study Completed NCT00569283 Phase 1

Search NIH Clinical Center for Chronic Eosinophilic Leukemia

Sources

Genetic Tests for Chronic Eosinophilic Leukemia

About this section
Sources

Anatomical Context for Chronic Eosinophilic Leukemia

About this section

MalaCards organs/tissues related to Chronic Eosinophilic Leukemia:

40
Bone Marrow, Bone, Myeloid, T Cells, Liver, Spinal Cord
Sources

Publications for Chronic Eosinophilic Leukemia

About this section

Articles related to Chronic Eosinophilic Leukemia:

(show top 50) (show all 265)
# Title Authors PMID Year
1
Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. 61
33367563 2021
2
Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. 61
33714638 2021
3
ATG5 promotes eosinopoiesis, but inhibits eosinophil effector functions. 61
33598715 2021
4
Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad Mass. 61
33616851 2021
5
A Case of Chronic Eosinophilic Leukemia in a Patient With Recurrent Cough, Dyspnea, and Eosinophilia. 61
33585139 2021
6
Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. 61
33166908 2020
7
Update on CML-Like Disorders. 61
32862848 2020
8
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic. 61
32243620 2020
9
ETV6-ACSL6 fusion gene in myeloid neoplasms: clinical spectrum, current practice, and outcomes. 61
32723365 2020
10
A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. 61
32533865 2020
11
Feasibility of Combined Detection of Gene Mutations and Fusion Transcripts in Bone Marrow Trephines from Leukemic Neoplasms. 61
32036087 2020
12
S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells. 61
32903598 2020
13
The Efficacy of Imatinib Mesylate in the Treatment of a Rare Lytic Bone Lesion Caused by Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia: A Case Report. 61
32224679 2020
14
Presentation of a diagnostically challenging case of chronic eosinophilic leukemia with marrow dysplasia and ringed sideroblasts. 61
33414919 2020
15
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. 61
31697804 2019
16
Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. 61
31421946 2019
17
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. 61
31423623 2019
18
[Hypereosinophilic syndromes]. 61
32233322 2019
19
Causes of eosinophilic ascites - A systematic review. 61
30864403 2019
20
A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31). 61
30697976 2019
21
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. 61
30573779 2019
22
Clonal evolution revealed by next-generation sequencing in a long-term follow-up patient with hypereosinophilia. 61
31024795 2019
23
A multimodality work-up of patients with Hypereosinophilia. 61
30105844 2018
24
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34). 61
29384404 2018
25
A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. 61
30032299 2018
26
Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm. 61
29505472 2018
27
[Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia]. 61
30032569 2018
28
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib. 61
28651427 2018
29
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. 61
29544149 2018
30
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. 61
29426921 2018
31
[Chronic myeloid leukemia presenting with marked eosinophilia]. 61
30626795 2018
32
A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. 61
29892549 2018
33
A Very Rare Case of Hypereosinophilic Syndrome Secondary to Natural Killer/T-Cell Lymphoma. 61
29785315 2018
34
Recurrent Malignancy-Associated Atypical Neutrophilic Dermatosis With Noninfectious Shock. 61
29208261 2017
35
World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. 61
29044676 2017
36
A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. 61
29025582 2017
37
Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report. 61
28885361 2017
38
Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL. 61
29029406 2017
39
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. 61
28495918 2017
40
Myeloid neoplasms with eosinophilia. 61
28028030 2017
41
Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. 61
27960034 2017
42
Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation. 61
27267816 2017
43
Integration of a bacterial gene sequence into a chronic eosinophilic leukemia patient's genome as part of a fusion gene linker. 61
28593047 2017
44
When Hypereosinophilia Leads to Stroke. 61
30755950 2017
45
Early-Stage Loeffler's Endocarditis with Isolated Right Ventricular Involvement: Management, Long-Term Follow-Up, and Review of Literature. 61
27172873 2016
46
Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement. 61
27722133 2016
47
Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia. 61
27458550 2016
48
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. 61
27174585 2016
49
Chronic Eosinophilic Leukemia Presenting Predominantly with Cutaneous Manifestations. 61
27512192 2016
50
Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. 61
26503642 2016
Sources

Variations for Chronic Eosinophilic Leukemia

About this section
Sources

Expression for Chronic Eosinophilic Leukemia

About this section
Search GEO for disease gene expression data for Chronic Eosinophilic Leukemia.
Sources

Pathways for Chronic Eosinophilic Leukemia

About this section

Pathways related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.95 SIGLEC8 PDGFRB PDGFRA OSM KIT JAK2
2
ERK Signaling 63
Show member pathways
 13.74 PDGFRB PDGFRA OSM KIT JAK2 IL5
3
PEDF Induced Signaling 63
Show member pathways
 13.57 PDGFRB PDGFRA OSM KIT JAK2 IL5
4
TGF-Beta Pathway 63
Show member pathways
 13.44 PDGFRB PDGFRA KIT JAK2 IL5 IFNA1
5
Akt Signaling 63
Show member pathways
 13.3 PDGFRB PDGFRA OSM KIT JAK2 IL5
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.26 PDGFRB PDGFRA OSM KIT JAK2 IL5
7
PAK Pathway 63
Show member pathways
 13.2 PDGFRB PDGFRA OSM KIT JAK2 IL5
8
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 12.85 PDGFRB PDGFRA KIT FLT3 FGFR1
9
PI3K-Akt signaling pathway 36
Show member pathways
 12.81 PDGFRB PDGFRA OSM KIT JAK2 IFNA1
10
Endometrial cancer 36
Show member pathways
 12.77 TPM3 PDGFRB PDGFRA KIT FLT3 FGFR1
11
MAPK signaling pathway 36 1
12.66 PDGFRB PDGFRA KIT FLT3 FGFR1
12
Ras signaling pathway 36
Show member pathways
 12.65 PDGFRB PDGFRA KIT FLT3 FGFR1 ABL1
13
Apoptosis Pathway 69
Show member pathways
 12.36 PDGFRB PDGFRA IL5 FGFR1
14
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.29 PDGFRB PDGFRA KIT FLT3 FGFR1
15
JAK-STAT signaling pathway 36
Show member pathways
 12.28 PDGFRB PDGFRA OSM JAK2 IL5 IFNA1
16
Pathways in cancer 36
12.05 TPM3 PDGFRB PDGFRA KIT JAK2 IL5
17
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.01 PDGFRB PDGFRA KIT IL5 IFNA1 FGFR1
18
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.9 SIGLEC8 KIT IL5 FLT3
19
Hematopoietic cell lineage 36
11.81 KIT IL5 FLT3
20
Angiogenesis (CST) 4
11.75 PDGFRB PDGFRA FGFR1
21
VEGF Pathway (Tocris) 69
Show member pathways
 11.73 PDGFRB KIT FLT3 FGFR1
22
Tyrosine Kinases / Adaptors 4
11.67 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
23
Ponatinib Pathway, Pharmacokinetics/Pharmacodynamics 60
Show member pathways
 11.45 PDGFRB PDGFRA KIT ABL1
24
Alzheimers Disease Pathway 63
11.4 PDGFRB PDGFRA FGFR1
25
Central carbon metabolism in cancer 36
11.4 PDGFRB PDGFRA KIT FLT3 FGFR1
26
Vemurafenib Pathway, Pharmacodynamics 60
11.37 PDGFRB PDGFRA FGFR1
27
Pazopanib Pathway, Pharmacokinetics 60
Show member pathways
 11.15 PDGFRB PDGFRA KIT FLT3
28
G-protein signaling_Rap2B regulation pathway 23
10.9 PDGFRB PDGFRA OSM KIT IL5 FLT3
29
Osteoblast Signaling 1
10.78 PDGFRB PDGFRA
Sources

GO Terms for Chronic Eosinophilic Leukemia

About this section

Cellular components related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.02 PDGFRB PDGFRA KIT FLT3 FGFR1

Biological processes related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10.1 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
2 protein phosphorylation GO:0006468 10.07 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
3 positive regulation of cell proliferation GO:0008284 10.01 PDGFRB PDGFRA OSM KIT JAK2 IL5
4 cytokine-mediated signaling pathway GO:0019221 9.97 OSM KIT JAK2 IL5 IFNA1 FLT3
5 positive regulation of cell migration GO:0030335 9.95 PDGFRB PDGFRA KIT JAK2
6 positive regulation of protein kinase B signaling GO:0051897 9.93 PDGFRB PDGFRA OSM KIT FGFR1
7 positive regulation of MAPK cascade GO:0043410 9.88 OSM KIT FLT3 FGFR1
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 PDGFRB PDGFRA KIT FLT3 FGFR1
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 OSM JAK2 IL5 ABL1
10 MAPK cascade GO:0000165 9.87 PDGFRB PDGFRA KIT JAK2 IL5 FLT3
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 OSM KIT JAK2 FLT3
12 cell chemotaxis GO:0060326 9.83 PDGFRB PDGFRA KIT
13 B cell differentiation GO:0030183 9.81 KIT IFNA1 FLT3
14 hemopoiesis GO:0030097 9.81 KIT FLT3 ASXL1
15 positive regulation of MAP kinase activity GO:0043406 9.81 PDGFRB KIT FLT3 FGFR1
16 phosphatidylinositol-mediated signaling GO:0048015 9.79 PDGFRB PDGFRA FGFR1
17 positive regulation of kinase activity GO:0033674 9.77 PDGFRB PDGFRA KIT FLT3 FGFR1
18 platelet-derived growth factor receptor signaling pathway GO:0048008 9.76 PDGFRB PDGFRA JAK2 ABL1
19 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.73 PDGFRB PDGFRA KIT FLT3
20 protein autophosphorylation GO:0046777 9.7 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
21 negative regulation of cell-cell adhesion GO:0022408 9.66 JAK2 ABL1
22 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.65 PDGFRB JAK2
23 cardiac myofibril assembly GO:0055003 9.64 PDGFRB PDGFRA
24 metanephric mesenchyme development GO:0072075 9.63 WT1 PDGFRB
25 retina vasculature development in camera-type eye GO:0061298 9.62 PDGFRB PDGFRA
26 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.61 PDGFRB ABL1
27 myeloid progenitor cell differentiation GO:0002318 9.61 KIT FLT3
28 metanephric S-shaped body morphogenesis GO:0072284 9.6 WT1 PDGFRB
29 metanephric glomerular capillary formation GO:0072277 9.59 PDGFRB PDGFRA
30 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.58 PDGFRB PDGFRA
31 positive regulation of phospholipase C activity GO:0010863 9.56 PDGFRB PDGFRA KIT FGFR1
32 peptidyl-tyrosine phosphorylation GO:0018108 9.5 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
33 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.17 PDGFRB PDGFRA OSM KIT JAK2 FLT3

Molecular functions related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 WT1 U2AF1 TPM3 TET2 SIGLEC8 PDGFRB
2 kinase activity GO:0016301 9.8 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
3 protein kinase activity GO:0004672 9.7 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
4 growth factor binding GO:0019838 9.58 PDGFRB PDGFRA FLT3
5 SH2 domain binding GO:0042169 9.54 KIT JAK2 ABL1
6 platelet-derived growth factor receptor binding GO:0005161 9.49 PDGFRB PDGFRA
7 platelet-derived growth factor binding GO:0048407 9.48 PDGFRB PDGFRA
8 vascular endothelial growth factor-activated receptor activity GO:0005021 9.46 PDGFRA FLT3
9 vascular endothelial growth factor binding GO:0038085 9.43 PDGFRB PDGFRA
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.35 PDGFRB PDGFRA KIT FLT3 FGFR1
11 protein tyrosine kinase activity GO:0004713 9.17 PDGFRB PDGFRA KIT JAK2 FLT3 FGFR1
Sources

Sources for Chronic Eosinophilic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....